Table 1 Baseline characteristics
Characteristic | Total, n(%) | Patients, n (%) | |
|---|---|---|---|
Case group (n = 55) | Control group (n = 83) | ||
Median/years | 48.5(20–67) | 46(20–66) | 52(28–67) |
Range/years | |||
  < 60 years | 128(92.75) | 52(94.55) | 76(91.57) |
  ≥ 60 years | 10(7.25) | 3(5.45) | 7(8.43) |
Menopause status | |||
 Premenopausal | 83(60.14) | 38(69.09) | 45(54.22) |
 Postmenopausal | 55(39.86) | 17(30.91) | 38(45.78) |
ECOG performance status | |||
 0 | 118(85.51) | 47(85.45) | 71(85.54) |
 1 | 20(14.49) | 8(14.55) | 12(14.46) |
Primary tumor size | |||
 T1 | 8(5.80) | 3(5.45) | 5(6.02) |
 T2 | 86(62.32) | 32(58.18) | 54(65.06) |
 T3 | 44(31.88) | 20(36.36) | 24(28.92) |
Primary lymph node status | |||
 N0 | 31(22.46) | 13(23.64) | 18(21.69) |
 N1 | 44(31.88) | 19(34.55) | 25(30.12) |
 N2 | 51(36.96) | 20(36.36) | 31(37.35) |
 N3 | 12(8.70) | 3(5.45) | 9(10.84) |
Clinical stage | |||
 II | 62(44.93) | 26(47.27) | 36(43.37) |
 III | 76(55.07) | 29(52.73) | 47(56.63) |
Histologic stage | |||
 II | 99(71.74) | 41(74.55) | 58(69.88) |
 III | 39(28.26) | 14(25.45) | 25(30.12) |
ER | |||
 Positive | 63(45.65) | 21(38.18) | 42(50.60) |
 Negative | 75(54.35) | 34(61.82) | 41(49.40) |
PR | |||
 Positive | 54(39.13) | 19(34.55) | 35(42.17) |
 Negative | 84(60.87) | 36(65.45) | 48(57.83) |
AR | |||
 Positive | 117(84.78) | 47(85.45) | 70(84.34) |
 Negative | 21(15.22) | 8(14.55) | 13(15.66) |
Ki-67 levels | |||
  < 14% | 5(3.62) | 2(3.64) | 3(3.61) |
  ≥ 14% | 133(96.38) | 53(96.36) | 80(96.39) |